Clinical trial

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

NCT04434040

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Atezolizumab Normalized identity: atezolizumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Sacituzumab govitecan Normalized identity: sacituzumab govitecanView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2020-07-02

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Triple Negative Breast Cancercandidate · MONDO: triple-negative breast carcinoma

Residual Cancerunresolved

Circulating Tumor DNAunresolved

Interventions

AtezolizumabDRUG · verified · RxNorm: atezolizumab

Sacituzumab govitecanDRUG · verified · RxNorm: sacituzumab govitecan

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

Genentech, Inc.collaborator

Stand Up To Cancercollaborator

Mapped research locations

BostonMassachusetts, United States1 ChicagoIllinois, United States1 PhiladelphiaPennsylvania, United States1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04434040 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.